What does Seleniso treat and how is it used?

Selinisol, this innovative oral drug, has become an important option for the treatment of a series of refractory or relapsed hematological malignancies due to its unique pharmacological mechanism. It not only provides new treatment hope for patients who have poor response to traditional therapies or whose conditions relapse, but also shows excellent efficacy in a variety of complex treatment scenarios, bringing new treatment strategies to doctors and patients. What are the current main indications for this drug and how to use it?

The combination of selinesol with bortezomib and dexamethasone (i.e.,SVd regimen) has emerged as an effective treatment option for adult patients with multiple myeloma who have received at least one prior therapy. This combination can target disease progression, help patients control their condition, and improve their quality of life.

The combination of selinesol and dexamethasone also offers new treatment hope for patients with multiple myeloma who have experienced at least four prior therapies and whose disease is refractory to multiple drugs, including proteasome inhibitors, immunomodulators and anti-CD38 monoclonal antibodies.

In addition, selinesol is also used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL transformed from follicular lymphoma. For these patients, after at least two systemic treatments, the addition of selinesol can bring new opportunities to treatment.

When using selinesol, the recommended dosage and regimen must be strictly followed. When used in combination with bortezomib and dexamethasone, take 100 mg orally once a week on the first day of each week until disease progression or intolerable toxicity occurs. If used in combination with dexamethasone only, 80 mg taken orally on the first and third days of each week is recommended. For the treatment of lymphoma patients, it is recommended to take 60 mg orally on the first and third days of each week.

Each dose should be taken at approximately the same time of day, and each tablet should be swallowed with water. Tablets should not be broken, chewed, crushed, or divided. If a dose is missed or delayed, the next dose should be taken at the next regularly scheduled time. If a patient vomits a dose of medication, the dose should not be repeated but the next dose should be taken on the next regularly scheduled date.

In conclusion, selinesol, as an important therapeutic drug, plays a key role in the treatment of various refractory hematological malignancies. When using it, patients should strictly follow the doctor's instructions to ensure the correct use of the drug to achieve the best therapeutic effect. The drug is currently sold at home and abroad. Patients should choose the drug version according to their needs, but be sure to purchase it through formal channels and pay attention to distinguishing the authenticity from the fake.